TREATMENTS FOR BLOOD SUGAR LEVELS AND MUSCLE TISSUE OPTIMIZATION USING EXTRACORPOREAL ACOUSTIC SHOCK WAVES

• US 20170296427A1
• Filed: 04/18/2016
• Published: 10/19/2017
• Est. Priority Date: 04/18/2016
• Status: Active Grant

• Current Assignee: Softwave Tissue Regeneration Technologies, LLC
• Original Assignee: General Patent, LLC (Tissue Regeneration Technologies LLC)
• Inventors: Warlick, John, Vincent, Kenneth Craig S
• Granted Patent: US 11,389,370 B2
• Time in Patent Office: Days
• CPC Class Codes: A61F 5/41 Devices for promoting penis erection penis implants A61F2/26; massage of the genitals A61H19/00
• CPC Class Codes: A61H 19/30 Devices for external stimulation of the genitals
• CPC Class Codes: A61H 2203/0468 Prone
• CPC Class Codes: A61H 23/008 using shock waves
• CPC Class Codes: G10K 15/043 producing shock waves G10K15/046, G10K15/06 take precedence; generating seismic energy G01V1/02

Abstract

A method of treating red blood cells of a human patient has the steps of activating an acoustic shock wave generator or source to emit acoustic shock waves and subjecting a vascular system containing red blood cells and surrounding muscle tissue peripherally through an extremity of a patient to the acoustic shock waves by stimulating the extremity wherein the extremity is positioned within a path of the emitted shock waves and away from a geometric focal volume or point of the emitted shock waves. The methods also treat muscle tissue of aging patients, from muscle regeneration or athletes for legal performance enhancement without drugs.

Claims

1. A method of treating red blood cells of a human patient comprises the steps of:

activating an acoustic shock wave generator or source to emit acoustic shock waves; and

subjecting a vascular system containing red blood cells and the surrounding muscle tissue peripherally through an extremity of a patient to the acoustic shock waves by stimulating the extremity wherein the extremity is positioned within a path of the emitted shock waves and away from a geometric focal volume or point of the emitted shock waves.

2. The method of treating red blood cells of a human patient of claim 1 wherein the emitted shock waves are divergent or near planar.

3. The method of treating red blood cells of a human patient of claim 1 wherein the emitted shock waves are convergent having a geometric focal volume or point at a distance of at least X from the generator or source, the method further comprising positioning the extremity at a distance less than the distance X from the source.

4. The method of treating red blood cells of a human patient of claim 1 wherein the patient is diabetic exhibiting type 1 or type 2 diabetes condition.

5. The method of treating red blood cells of a human patient of claim 1 wherein the extremity is a leg.

6. The method of treating red blood cells of a human patient of claim 5 wherein the extremity is a foot.

7. The method of treating red blood cells of a human patient of claim 1 wherein the extremity is an arm.

8. The method of treating red blood cells of a human patient of claim 1 wherein the patient has an elevated baseline blood sugar level prior to treating which lowers after treatment.

9. The method of treating red blood cells of a human patient of claim 1 wherein repeating the method periodically a plurality of times over a period of weeks to lower said baseline level of blood sugar.

10. The method of preventive shock wave therapy comprises the steps of:

identifying a diabetic at risk patient, the patient having an at risk baseline blood sugar level; and

subjecting the at risk extremity to shock waves to lower said baseline sugar level.

11. The method of preventive shock wave therapy of claim 10 wherein the step of identifying an at risk patient includes one or more indications of risk based on family history, genetic disposition, physical condition, or blood or extremity analysis.

12. The method of preventive shock wave therapy of claim 10 further comprises the step of testing the at risk extremity to establish measured the baseline condition pre shock wave therapy.

13. The method of preventive shock wave therapy of claim 10 further comprises the step of post shockwave therapy testing the blood sugar level for comparison to the baseline condition.

14. The method of treating red blood cells of a human patient of claim 10 wherein repeating the method periodically a plurality of times over a period of weeks to lower said baseline level of blood sugar.

15. A method of treating skeletal muscle tissue of an aging human patient comprises the steps of:

activating an acoustic shock wave generator or source to emit acoustic shock waves; and

subjecting surrounding muscle tissue peripherally to the acoustic shock waves by stimulating the muscle tissue wherein the muscle tissue is positioned within a path of the emitted shock waves and away from a geometric focal volume or point of the emitted shock waves.

16. The method of treating an aging human patient of claim 15 wherein the emitted shock waves are divergent or near planar.

17. The method of treating an aging human patient of claim 15 wherein the emitted shock waves are convergent having a geometric focal volume or point at a distance of at least X from the generator or source, the method further comprising positioning the extremity at a distance less than the distance X from the source.

18. The method of treating an aging human patient of claim 15 wherein the patient is exhibiting one or more impairments such as:

age related skeletal muscle atrophy and sarcopenia resulting in the loss of muscle capacity and mass, progressive motor neuron degeneration, increases in fat mass, decreases in lean muscle, bone mass, and cellular environmental aberrances are commonly seen alterations of aging muscle, impairments in metabolic rate, aerobic capacity, strength and balance, functional capacity, along with emotional and cognitive distress.

19. The method of treating an aging human patient of claim 15 wherein the emitted shock waves are of a low intensity ranging from 0.10-0.12 mJ/mm².

20. A method of treating skeletal muscle tissue of a human patient to optimize athletic performance and muscle resilience comprises the steps of:

activating an acoustic shock wave generator or source to emit acoustic shock waves; and

subjecting surrounding muscle tissue peripherally to the acoustic shock waves by stimulating the muscle tissue wherein the muscle tissue is positioned within a path of the emitted shock waves and away from a geometric focal volume or point of the emitted shock waves.

21. The method of treating a human patient to optimize athletic performance and muscle resilience of claim 20 wherein the emitted shock waves are divergent or near planar.

22. The method of treating a human patient to optimize athletic performance and muscle resilience of claim 20 wherein the emitted shock waves are convergent having a geometric focal volume or point at a distance of at least X from the generator or source, the method further comprising positioning the extremity at a distance less than the distance X from the source.

23. The method of treating a human patient to optimize athletic performance and muscle resilience of claim 20 wherein the patient is exhibiting one or more impairments such as:

age related skeletal muscle atrophy and sarcopenia resulting in the loss of muscle capacity and mass, progressive motor neuron degeneration, increases in fat mass, decreases in lean muscle, bone mass, and cellular environmental aberrances are commonly seen alterations of aging muscle, impairments in metabolic rate, aerobic capacity, strength and balance, functional capacity, along with emotional and cognitive distress.

24. The method of treating a human patient to optimize athletic performance and muscle resilience of claim 20 wherein the emitted shock waves are of a low intensity ranging from 0.10-0.14 mJ/mm².

25. The method of treating a human patient to optimize athletic performance and muscle resilience of claim 20 wherein the emitted shock waves cause a quick removal of lactic acid from the cells of the muscle tissue allowing quicker muscle recovery.

26. The method of treating a human patient to optimize athletic performance and muscle resilience of claim 20 wherein the treatment causes rapid recovery from muscle cramping.

27. The method of treating a human patient to optimize athletic performance and muscle resilience of claim 20 wherein the treatment is used for erectile dysfunction or penis performance enhancement.